| Atrium Post Acute Care Of Woodbury | |
| 467 Cooper Street, Woodbury, New Jersey 08096 | |
| (856) 345-1200 | |
| Name | Atrium Post Acute Care Of Woodbury |
|---|---|
| Location | 467 Cooper Street, Woodbury, New Jersey |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 124 |
| Occupancy Rate | 27.66% |
| Medicare ID (CCN) | 315521 |
| Legal Business Name | 467 Cooper St Operating Company Llc |
| Ownership Type | For Profit - Limited Liability Company |
| NPI Number | 1508424623 |
| Organization Name | WOODBURY AMOP, LLC |
| Doing Business As | SPRING HILLS POST ACUTE WOODBURY |
| Address | 467 Cooper St, Woodbury, NJ 08096 |
| Phone Number | 856-345-1200 |
News Archive
To ensure normal fetal development and prevent disease, it is crucial that certain genes are on or off in the right time intervals. Researchers in Professor Kristian Helin's group at BRIC, University of Copenhagen, have now shown how the TET1 enzyme controls the activity of our genes. The results are just published in the journal Nature.
Fibrin, the chief ingredient of blood clots, is a remarkably versatile polymer. On one hand, it forms a network of fibers - a blood clot - that stems the loss of blood at an injury site while remaining pliable and flexible. On the other hand, fibrin provides a scaffold for thrombi, clots that block blood vessels and cause tissue damage, leading to myocardial infarction, ischemic stroke, and other cardiovascular diseases. How does fibrin manage to be so strong and yet so extensible under the stresses of healing and blood flow?
Food systems face growing threats as extreme weather events become more common and more extreme due to climate change.
Later this week, Cardinal Health Specialty Solutions will present a new series of health economic outcomes research (HEOR) studies that reinforce the importance of evaluating real-world treatment patterns when developing value-based reimbursement strategies.
Abraxis BioScience, Inc., a fully integrated, global biotechnology company, today announced that Taiho Pharmaceutical Co., Ltd. has received approval from the Ministry of Health, Labor and Welfare to market ABRAXANE IV Infusion 100 mg, Paclitaxel Injection (Suspension with Albumin), for use in the treatment of breast cancer. The New Drug Application (J-NDA) for ABRAXANE was filed with the Ministry of Health, Labor and Welfare in 2008.
› Verified 2 days ago
| NPI Number | 1891406013 |
| Organization Name | WOODBURY SNF OPERATIONS LLC |
| Address | 467 Cooper St, Woodbury, NJ 08096 |
| Phone Number | 856-345-1200 |
News Archive
To ensure normal fetal development and prevent disease, it is crucial that certain genes are on or off in the right time intervals. Researchers in Professor Kristian Helin's group at BRIC, University of Copenhagen, have now shown how the TET1 enzyme controls the activity of our genes. The results are just published in the journal Nature.
Fibrin, the chief ingredient of blood clots, is a remarkably versatile polymer. On one hand, it forms a network of fibers - a blood clot - that stems the loss of blood at an injury site while remaining pliable and flexible. On the other hand, fibrin provides a scaffold for thrombi, clots that block blood vessels and cause tissue damage, leading to myocardial infarction, ischemic stroke, and other cardiovascular diseases. How does fibrin manage to be so strong and yet so extensible under the stresses of healing and blood flow?
Food systems face growing threats as extreme weather events become more common and more extreme due to climate change.
Later this week, Cardinal Health Specialty Solutions will present a new series of health economic outcomes research (HEOR) studies that reinforce the importance of evaluating real-world treatment patterns when developing value-based reimbursement strategies.
Abraxis BioScience, Inc., a fully integrated, global biotechnology company, today announced that Taiho Pharmaceutical Co., Ltd. has received approval from the Ministry of Health, Labor and Welfare to market ABRAXANE IV Infusion 100 mg, Paclitaxel Injection (Suspension with Albumin), for use in the treatment of breast cancer. The New Drug Application (J-NDA) for ABRAXANE was filed with the Ministry of Health, Labor and Welfare in 2008.
› Verified 2 days ago
| NPI Number | 1952776395 |
| Organization Name | 467 COOPER ST OPERATING COMPANY LLC |
| Doing Business As | ATRIUM POST ACUTE CARE OF WOODBURY |
| Address | 467 Cooper St, Woodbury, NJ 08096 |
| Phone Number | 856-242-3351 |
News Archive
To ensure normal fetal development and prevent disease, it is crucial that certain genes are on or off in the right time intervals. Researchers in Professor Kristian Helin's group at BRIC, University of Copenhagen, have now shown how the TET1 enzyme controls the activity of our genes. The results are just published in the journal Nature.
Fibrin, the chief ingredient of blood clots, is a remarkably versatile polymer. On one hand, it forms a network of fibers - a blood clot - that stems the loss of blood at an injury site while remaining pliable and flexible. On the other hand, fibrin provides a scaffold for thrombi, clots that block blood vessels and cause tissue damage, leading to myocardial infarction, ischemic stroke, and other cardiovascular diseases. How does fibrin manage to be so strong and yet so extensible under the stresses of healing and blood flow?
Food systems face growing threats as extreme weather events become more common and more extreme due to climate change.
Later this week, Cardinal Health Specialty Solutions will present a new series of health economic outcomes research (HEOR) studies that reinforce the importance of evaluating real-world treatment patterns when developing value-based reimbursement strategies.
Abraxis BioScience, Inc., a fully integrated, global biotechnology company, today announced that Taiho Pharmaceutical Co., Ltd. has received approval from the Ministry of Health, Labor and Welfare to market ABRAXANE IV Infusion 100 mg, Paclitaxel Injection (Suspension with Albumin), for use in the treatment of breast cancer. The New Drug Application (J-NDA) for ABRAXANE was filed with the Ministry of Health, Labor and Welfare in 2008.
› Verified 2 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
To ensure normal fetal development and prevent disease, it is crucial that certain genes are on or off in the right time intervals. Researchers in Professor Kristian Helin's group at BRIC, University of Copenhagen, have now shown how the TET1 enzyme controls the activity of our genes. The results are just published in the journal Nature.
Fibrin, the chief ingredient of blood clots, is a remarkably versatile polymer. On one hand, it forms a network of fibers - a blood clot - that stems the loss of blood at an injury site while remaining pliable and flexible. On the other hand, fibrin provides a scaffold for thrombi, clots that block blood vessels and cause tissue damage, leading to myocardial infarction, ischemic stroke, and other cardiovascular diseases. How does fibrin manage to be so strong and yet so extensible under the stresses of healing and blood flow?
Food systems face growing threats as extreme weather events become more common and more extreme due to climate change.
Later this week, Cardinal Health Specialty Solutions will present a new series of health economic outcomes research (HEOR) studies that reinforce the importance of evaluating real-world treatment patterns when developing value-based reimbursement strategies.
Abraxis BioScience, Inc., a fully integrated, global biotechnology company, today announced that Taiho Pharmaceutical Co., Ltd. has received approval from the Ministry of Health, Labor and Welfare to market ABRAXANE IV Infusion 100 mg, Paclitaxel Injection (Suspension with Albumin), for use in the treatment of breast cancer. The New Drug Application (J-NDA) for ABRAXANE was filed with the Ministry of Health, Labor and Welfare in 2008.
› Verified 2 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|